Our Management
Jon Zwinski was named General Manager and Chief Executive Officer in January 2021. Since joining Chiesi USA in 2012, he has held numerous executive positions focused on the growth of the company’s commercial organization across multiple therapeutic categories. Immediately prior to his current role, he served as Senior Vice President of Sales and Head of the Cardiovascular Business Unit.
In his 25+ year career as a pharmaceutical executive, Mr. Zwinski has worked in multiple therapeutic areas, including anesthesia, women’s health, emergency medicine, psychiatry, neurology, neonatology, urology, cardiovascular, and cystic fibrosis. He previously held positions at Organon Pharmaceuticals, PDL BioPharma, and EKR Therapeutics, where he was Vice President of Sales before joining Chiesi USA.
Alan T. Roberts has served as Senior Vice President, Scientific Affairs/Compliance Officer since November 2015. Mr. Roberts joined the company as Vice President, Scientific Affairs in 2009. Prior to joining the company, Mr. Roberts founded Tybeam Pharma Consulting, LLC and served as its President. Previously, Mr. Roberts served as Senior Vice President and Chief Scientific Officer for Auriga Laboratories, Inc. Mr. Roberts also held various leadership positions at First Horizon Pharmaceutical Corporation and Mikart. In addition, Mr. Roberts held key management positions in regulatory and development at Solvay Pharmaceuticals, Inc.
Mr. Roberts holds a Bachelor of Science in Microbiology from Clemson University.
Michael R. Gordon joined the company as Vice President, Legal Affairs and General Counsel in 2014. Prior to joining the company, Mr. Gordon practiced law for almost twenty years. He began his career as an Assistant District Attorney in New York City in the Manhattan District Attorney’s Office under the Honorable Robert M. Morgenthau. Mr. Gordon also served as an associate and partner at the Raleigh, North Carolina law firm of Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, LLP. Most recently, Mr. Gordon was a partner in the Research Triangle Park, North Carolina office of the international law firm of K&L Gates, LLP.
Mr. Gordon is admitted to the North Carolina and New York state bar. He earned a J.D. from Brooklyn Law School and a B.A. from Tulane University.
Jason Beyer has served as Vice President – Business Unit Leader, Neonatology/Cystic Fibrosis (CF) since January 2021. Mr. Beyer joined the company as Product Manager, Neonatology in 2009. Since that time, he has held leadership positions within the Marketing and the Strategy & Corporate Development departments at Chiesi USA and held a strategic role within the Chiesi SpA Global Marketing team based in Parma, Italy. Before joining the company, Mr. Beyer held multiple commercial positions in marketing and sales at Sanofi Genzyme.
Mr. Beyer holds a Bachelor of Arts in Economics from Bates College, and a Masters of Business Administration from the Duke University Fuqua School of Business.
Jay Meyer has served as Vice President – Business Unit Leader, Critical Care since January 2021. Mr. Meyer joined the company in 2014 as Sr. National Sales Director and has served in sales leadership positions across the business, including his most recent role as Sr. National Sales Director, Cardiovascular Hospital, to which he was appointed in 2017. He began his career as a field sales representative for Eli Lilly and progressed into multiple sales and marketing leadership roles. Mr. Meyer has broad experience in many therapeutic areas including cardiovascular, oncology, pain, respiratory, infectious disease, hepatology, and multiple rare diseases in large, established organizations as well as in start-up environments.
Mr. Meyer holds a BSBA from Ohio Northern University and a Master of Business Administration from Xavier University.
Chiesi Canada Director of Commercial Operations, Americas, John oversees the US and South American rare disease commercial efforts including strategic marketing, sales, market access, government pricing and reimbursement.
Prior to this John was the Director of Sales for Apobiologix, where he led the commercial planning and go-to-market strategy for the newly formed biosimilar franchise in the US.
John has 25 years of industry experience and has held numerous senior commercial roles in oncology and cardiovascular franchises within start-up to large multinational organizations.
